2025
Actuate Therapeutics’ Pancreatic Cancer Drug Elraglusib Shows Survival Benefit in Phase 2 Study
Actuate Therapeutics; Elraglusib; Pancreatic cancer; Phase 2 trial; Median overall survival; Gemcitabine; Nab-paclitaxel; Metastatic pancreatic ductal adenocarcinoma; Survival benefit; ASCO 2025
J&J’s Akeega Advances PARP Inhibition in Prostate Cancer, but FDA Pathway in Broader Patient Subsets Remains Unclear
Akeega; J&J; prostate cancer; PARP inhibitor; FDA approval; BRCA mutations; HRR gene alterations; AMPLITUDE study; metastatic castration-sensitive prostate cancer (mCSPC); metastatic castration-resistant prostate cancer (mCRPC)
Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win
Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy
BioAge Signs Option Agreement for Obesity Asset from Chinese Biotech Following APJ Agonist Setback
BioAge; JiKang Therapeutics; obesity; APJ agonist; option agreement; nanobody; small molecule agonists; exercise mimetic; incretin therapy; metabolic diseases
Bristol Myers CMO Addresses LAG-3 Concerns After Opdualag’s Adjuvant Melanoma Setback at ASCO 2025
Opdualag; Bristol Myers Squibb; LAG-3; lung cancer; adjuvant melanoma; ASCO 2025; Opdivo; relatlimab; clinical trial
OSE Immunotherapeutics Reports 65% Overall Survival Rate in Phase 2 Cancer Vaccine Trial at ASCO 2025
OSE Immunotherapeutics; Tedopi; ASCO 2025; pancreatic cancer; neo-epitope cancer vaccine; phase 2; overall survival rate
Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal
Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments
Kymera Soars on Early Protein Degrader Data
Kymera Therapeutics; KT-621; STAT6 degrader; protein degradation; Phase 1 clinical trial; autoimmune disease
Regeneron Licenses Hansoh’s GLP-1/GIP Obesity Drug to Compete with Zepbound
Regeneron; Hansoh Pharmaceuticals; HS-20094; GLP-1/GIP receptor agonist; obesity drug; Zepbound; Eli Lilly; obesity treatment; licensing deal; biopharma